TY - JOUR AB - Following the publication of this article, the authors have realized that Table I contained an error: The number of patients who were alive in the Rab22a high expression group should have been written as 77 instead of 772.
A corrected version of the Table is shown on the next page (the corrected datum is highlighted in bold). The authors sincerely apologize for the error that was introduced during the preparation of this Table, and regret any inconvenience that this mistake has caused. [the original article was published in International Journal of Molecular Medicine 45: 1037-1046, 2020; DOI: 10.3892/ijmm.2020.4486] AD - Department of Anesthesia, The Second Hospital of Jilin University, Changchun, Jilin 130022, P.R. China Department of General Surgery, Xi'an Central Hospital, Xi'an, Shanxi 710000, P.R. China Department of Pathology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China Department of Breast Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China AU - He,Miao AU - Shen,Leihua AU - Jiang,Chengwei AU - Gao,Ge AU - Wang,Keren AU - Jiao,Yan AU - Sun,Liang AU - Cui,Yingnan AU - Ke,Zirui AU - Yang,Zhaoying DA - 2021/03/01 DO - 10.3892/ijmm.2021.4851 IS - 3 JO - Int J Mol Med KW - Rab22a prognosis progression breast cancer PY - 2021 SN - 1107-3756 1791-244X SP - 18 ST - [Corrigendum] Rab22a is a novel prognostic marker for cell progression in breast cancer T2 - International Journal of Molecular Medicine TI - [Corrigendum] Rab22a is a novel prognostic marker for cell progression in breast cancer UR - https://doi.org/10.3892/ijmm.2021.4851 VL - 47 ER -